Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Phosphoinositide-3-Kinase, Catalytic, alpha Polypeptide (PIK3CA) (Middle Region) Peptid

PIK3CA Reaktivität: Human Wirt: Synthetic BP, WB
Produktnummer ABIN5512434

Kurzübersicht für Phosphoinositide-3-Kinase, Catalytic, alpha Polypeptide (PIK3CA) (Middle Region) Peptid (ABIN5512434)

Target

PIK3CA (Phosphoinositide-3-Kinase, Catalytic, alpha Polypeptide (PIK3CA))

Spezies

Human

Quelle

  • 3
Synthetic

Applikation

Blocking Peptide (BP), Western Blotting (WB)
  • Protein Region

    Middle Region

    Sequenz

    IIVVIWVIVS PNNDKQKYTL KINHDCVPEQ VIAEAIRKKT RSMLLSSEQL

    Produktmerkmale

    This is a synthetic peptide designed for use in combination with anti-PIK3CA Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
  • Applikationshinweise

    Optimal working dilution should be determined by the investigator.

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Format

    Lyophilized

    Rekonstitution

    Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.

    Lagerung

    -20 °C

    Informationen zur Lagerung

    For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
  • Target

    PIK3CA (Phosphoinositide-3-Kinase, Catalytic, alpha Polypeptide (PIK3CA))

    Hintergrund

    Phosphatidylinositol 3-kinase is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. The protein encoded by this gene represents the catalytic subunit, which uses ATP to phosphorylate PtdIns, PtdIns4P and PtdIns(4,5)P2. This gene has been found to be oncogenic and has been implicated in cervical cancers.

    Alias Symbols: MCM, CWS5, MCAP, PI3K, CLOVE, MCMTC, p110-alpha

    Protein Size: 1608

    Gen-ID

    5290

    NCBI Accession

    NM_006218, NP_006209

    UniProt

    P42337
Sie sind hier:
Chat with us!